General

No CPD Points

Course Summary

Polly Dulley & Philip Morgan (15:23)

Tamoxifen had resurfaced in 2013 in the media because of NICE guidelines which approved the drug for prescription not only to patients with a diagnosis, but also to those at high risk of developing breast cancer. Polly Dulley and Philip Morgan discuss the clinical impact that the NICE guidelines may have on optometrists.

First published in DOCET OQ87 (2013).

    Audio track (~15 mins)►

    Learning objectives

    Learning objectives

    To provide listeners with:

    • An overview of Tamoxifen, how it works and why it is so widely used
    • An outline of the NICE guideline relating to Tamoxifen
    • An outline of the ocular side-effects, how to examine for them, and how common they are
    • An indication of what an optometrist should bear in mind when dealing with a patient taking Tamoxifen
    • An indication of the impact the NICE guidelines will have on the numbers of patients optometrists see
      Audio track (~15 mins)►